Allogene Therapeutics (ALLO) Other financing activities (2019 - 2026)

Allogene Therapeutics (ALLO) has 8 years of Other financing activities data on file, last reported at $450000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $450000.0; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (up 91.86% YoY), and the FY2025 full-year result was $6.9 million, up 749.69% from the prior year.
• Other financing activities declined to $450000.0 in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $6.3 million in Q3 2025 to a low of -$2.0 million in Q4 2022.
• A 5-year average of $1.3 million and a median of $856000.0 in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities tumbled 123.12% in 2022 and soared 823.42% in 2025, its largest moves.
• Tracing ALLO's Other financing activities over 5 years: stood at -$2.0 million in 2022, then surged by 205.83% to $2.1 million in 2023, then advanced by 10.21% to $2.3 million in 2024, then jumped by 172.61% to $6.3 million in 2025, then plunged by 92.82% to $450000.0 in 2026.
• Business Quant data shows ALLO's Other financing activities at $450000.0 in Q1 2026, $6.3 million in Q3 2025, and $638000.0 in Q2 2025.